Related Experiment Videos
Current recommendations and future prospects in the treatment of toxoplasmosis
1Medical Service, Veterans Administration Medical Center, Martinez, California.
Abstract:
Toxoplasma infection is highly prevalent throughout the world and causes disease in diverse populations. Effective treatment regimens are available for each clinical entity of toxoplasma, but problems of incomplete clinical efficacy, drug potency, drug safety, and length of treatment remain. No well-controlled clinical trials in humans have been performed to evaluate the efficacy and safety of treatment. Primary treatment of toxoplasmosis is with the synergistic combination of pyrimethamine and sulphonamide. This is considered the treatment of choice for severe disease, disease in immunocompromised patients, and congenital toxoplasmosis. Spiramycin, a macrolide antibiotic, is frequently used alone or alternately with pyrimethamine and sulphonamide for pregnant women with the acute acquired infection to prevent congenital toxoplasmosis. Clindamycin is used frequently to treat acute flares of toxoplasmic chorioretinitis and as second-line therapy for toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome (AIDS). Inadequacies in the treatment of toxoplasmosis in immunosuppressed patients, exemplified by experience with AIDS patients, should provide the impetus for well-designed trials to find and evaluate more potent and better-tolerated agents. Classes of new drugs that have been investigated and show some promise include: (a) macrolides (roxithromycin, azithromycin); (b) folic acid antagonists (piritrexim and trimetrexate), and (c) purine analogues (arprinocid). Immunomodulators have attracted interest, and interferon-gamma alone and in combination with roxithromycin is effective in murine models. Interleukin-2 is also effective in the murine model.
Insights
Toxoplasmosis treatment faces challenges with efficacy and safety. New drug classes and immunomodulators show promise, but well-controlled human trials are needed to find better therapies for toxoplasmosis.
Area of Science:
- Infectious Diseases
- Pharmacology
- Immunology
Background:
- Toxoplasma infection is a widespread global health concern affecting various populations.
- Current treatments for toxoplasmosis have limitations including incomplete efficacy, safety concerns, and prolonged treatment durations.
- No robust clinical trials in humans have assessed the efficacy and safety of existing toxoplasmosis treatments.
Purpose of the Study:
- To review current treatment strategies for toxoplasmosis.
- To identify existing challenges in toxoplasmosis therapy.
- To explore novel therapeutic agents and approaches for toxoplasmosis.
Main Methods:
- Literature review of current and investigational treatments for toxoplasmosis.
- Analysis of drug efficacy, safety, and clinical trial data (where available).
- Examination of emerging drug classes and immunomodulatory agents in preclinical models.
Main Results:
- Pyrimethamine and sulphonamide are primary treatments for severe, opportunistic, and congenital toxoplasmosis.
- Spiramycin and clindamycin are used in specific scenarios, including pregnancy and acquired immunodeficiency syndrome (AIDS)-related toxoplasmosis.
- New drug classes like macrolides, folic acid antagonists, and purine analogues show potential, alongside immunomodulators like interferon-gamma and interleukin-2 in animal models.
Conclusions:
- Despite available treatments, significant challenges remain in managing toxoplasmosis, particularly in immunocompromised individuals.
- The limitations of current therapies highlight the urgent need for well-designed clinical trials to evaluate new agents.
- Investigational drugs and immunomodulatory approaches offer promising avenues for developing more effective and safer treatments for toxoplasmosis.